Autopsy report · NCT05192174

Study of NIB101 in Participants With Advanced Solid Tumors

“due to the reconsideration of development strategy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 4 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Noile-Immune Biotech, Inc

Sponsor type

Industry

Conditions

Solid Tumor

Interventions

NIB101

Participants

3

Sites

2

Countries

Japan

Trials that died the same way

• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (82% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (75% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (73% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (73% match in meaning)
• A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
  “Alternate development strategy” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.